The World Health Organization recommends that all hepatitis C virus-infected patients with hepatitis C virus replication (HCV RNA positive) should be considered for standardized antiviral therapy, regardless of whether they present with abnormal liver function, as long as there are no contraindications to antiviral therapy; patients with significant liver fibrosis should begin treatment immediately. WHO recommended treatment procedures for HCV-infected patients: Hepatitis C is curable. The goal of hepatitis C treatment is twofold: first, to clear the hepatitis C virus, improve liver disease, and prevent and reduce the development of cirrhosis and liver cancer. The second is to reduce the continued transmission of hepatitis C. The earlier the treatment of hepatitis C virus-infected patients, the better the results, more than 90% can achieve complete clearance of the virus and complete cure of the disease; patients with significant fibrosis of the liver or cirrhosis already formed can stop or delay the continued progression of liver disease, reduce the occurrence of decompensated cirrhosis and and hepatocellular carcinoma, and reduce the rate of death directly or indirectly related to hepatitis C. Cured patients with hepatitis C virus infection are no longer infectious, reducing the transmission of the hepatitis C virus. The standard treatment for hepatitis C is interferon + ribavirin. For patients who fail or cannot tolerate interferon + ribavirin therapy, a new generation of direct antiviral agents is available. These new generation direct antivirals have been marketed in many foreign countries and regions, and clinical trials are underway in China and will be available in China soon. More than 90% of people infected with hepatitis C virus can be cured with standardized antiviral therapy. Before treatment, the stage of hepatitis C disease development and the genotype of the virus should be evaluated, and the antiviral treatment plan should be selected under the guidance of a doctor; during the treatment period, regular reviews should be conducted at the hospital to assess the efficacy of the drugs and monitor drug toxicity.